

IN THE SPECIFICATION

Please amend the specification as indicated in the attached Marked-up Version of the Specification, which is accompanied by the Clean Version of the Specification, and as indicated below.

On page 14, lines 14-15: delete the phrase “, second order or pseudo second order”.

On page 16, line 27: delete the phrase “,second order”.

IN THE CLAIMS

Please amend the claims as indicated in the attached Marked-up Version of the Claims, which is accompanied by the Clean Version of the Claims, and as indicated below.

Please cancel claims 49-63, 75-105, and 123-132.

On line 4 of claim 1: add -- , duloxetine -- after “darifenacin”.

On line 4 of claim 13: add -- , duloxetine -- after “darifenacin”.

On line 4 of claim 30: add -- , duloxetine -- after “darifenacin”.


On line 4 of claim 64: add -- , duloxetine -- after “darifenacin”.


On line 4 of claim 112: add -- , duloxetine -- after “darifenacin”.

Applicants request that this preliminary amendment be fully considered and entered into the record of the above-identified patent application.

Respectfully submitted,

Date: 3/11/02
Innovar, L.L.C.
P.O. Box 250647
Plano, TX 75025-0647
Ph.: 972-747-7373
Fax: 972-747-7375


Rick Matos, Ph.D. (Registration No. 40,082)
Customer No. 24,039
Agent for Applicant
Email: innovarllc@mindspring.com



Marked-Up Version of Specification

- 14 -

wherein, when the osmotic device is exposed to an aqueous environment, oxybutynin is released according to a release profile as described herein.

Other specific embodiments of the invention include those wherein: 1) the osmotic device provides a single dose plasma level for darifenacin is sufficient to provide a desired therapeutic response in a subject; 2) the osmotic device provides a single dose plasma level for oxybutynin in the range of about 4-7 or 1-10 ng per ml of plasma; 3) the osmotic device provides a single dose plasma level for tolterodine in the range of about 0.5-25 ng per ml of plasma; or 4) the osmotic device comprises a finish coat exterior to the semipermeable membrane.

The invention also provides a therapeutic device for the delivery of pharmaceutically active agents, ranging in solubility from slightly soluble to very soluble drugs, in a controlled, continuous and approximately steady, preferably zero order, rate over a prolonged period of time. Depending upon the excipients used, among other things, the osmotic device can also deliver drugs according to first order, pseudo-first order, ~~second order or pseudo-second order~~ release profiles. In addition, the osmotic device may provide targeted delivery of a drug.

The device of the present invention is optionally provided with an external coating disposed on the outside of the osmotic device and comprising one or more active agents for immediate delivery to the environment of use. The external coating can contain a loading dose of an active agent in the core of the device.

Active agents useful in the delivery device include, for example, compounds such as biologically or pharmacologically active agents, medicines, nutrients, food products, insecticides, pesticides, herbicides, germicides, algacides, fungicides, chemical reagents, growth regulating substances, parasiticides, sex sterilants, fertility promoters, biocides, rodenticides, disinfectants, anti-oxidants, plant growth promoters, preservatives, fermentation agents, fertility inhibitors, deodorants, micro-organism attenuators, catalysts, food supplements, cosmetics, vitamins, and other agents that benefit the environment of use.

The osmotic device of the invention may be used in biological environments, aquariums, industrial warehouses, laboratory facilities, hospitals, chemical reactions and other facilities.

- 16 -

In one embodiment, oxybutynin and the second drug are released concurrently from a dosage form when the two drugs are included together in, for example, a tablet core, powder, capsule, bead, granule, liquid, paste, gel, cream, ointment, patch, implant or other similar dosage form capable of simultaneously delivering two or more drugs.

5 In another embodiment, oxybutynin and the second drug are released sequentially from a dosage form when the first drug is included in one part of a dosage form and the second drug is included in another part of the same dosage form, and release of the second drug begins shortly after, during or nearly at the end of completion of release of the first drug. Such dosage form would include, for example, those wherein the first drug is
10 included in a core and the second drug is included in a coat surrounding the core, a bi-layered tablet with each drug being in a different part of the core, a dosage form providing a rapid release of the first drug and a controlled release of the second drug. Suitable dosage forms for this embodiment include, for example, a layered patch, layered or coated tablet or bead, layered or coated osmotic device, capsule containing a mixture of beads
15 that provide different release profiles for the drugs, layered or coated implant, or an admixture of two compositions each containing a drug.

In yet another embodiment, oxybutynin and the second drug are released in spaced apart periods of time from a dosage form such that the first drug is released during a first period of time and the second drug is released during a later second period of time.
20 Dosage forms suitable for this type of release are generally considered targeted, enteric or timed-release dosage forms. Suitable dosage forms for this embodiment include, for example, a layered patch, layered or coated tablet, layered or coated osmotic device, capsule containing a mixture of beads that provide different release profiles for the drugs, and layered or coated implant.

25 Each drug will be released independently from a solid dosage form according to a rapid, immediate, controlled, sustained, slow, timed, targeted, pseudo-first order, first order, pseudo-zero order, zero-order~~[second order]~~ and/or delayed release profile. The particular release profiles for oxybutynin and the second drug in a particular dosage form will depend upon the specific combination of oxybutynin and second drug present and the
30 excipients used to make the dosage form. For example, a dosage form might provide: 1) a controlled release of the first drug and a controlled release of the second drug; 2) a controlled release of the second drug and a rapid release of the first drug; 3) a controlled

- 14 -

wherein, when the osmotic device is exposed to an aqueous environment, oxybutynin is released according to a release profile as described herein.

Other specific embodiments of the invention include those wherein: 1) the osmotic device provides a single dose plasma level for darifenacin is sufficient to provide a desired therapeutic response in a subject; 2) the osmotic device provides a single dose plasma level for oxybutynin in the range of about 4-7 or 1-10 ng per ml of plasma; 3) the osmotic device provides a single dose plasma level for tolterodine in the range of about 0.5-25 ng per ml of plasma; or 4) the osmotic device comprises a finish coat exterior to the semipermeable membrane.

10 The invention also provides a therapeutic device for the delivery of pharmaceutically active agents, ranging in solubility from slightly soluble to very soluble drugs, in a controlled, continuous and approximately steady, preferably zero order, rate over a prolonged period of time. Depending upon the excipients used, among other things, the osmotic device can also deliver drugs according to first order, pseudo-first order, 15 release profiles. In addition, the osmotic device may provide targeted delivery of a drug.

The device of the present invention is optionally provided with an external coating disposed on the outside of the osmotic device and comprising one or more active agents for immediate delivery to the environment of use. The external coating can contain a loading dose of an active agent in the core of the device.

20 Active agents useful in the delivery device include, for example, compounds such as biologically or pharmacologically active agents, medicines, nutrients, food products, insecticides, pesticides, herbicides, germicides, algacides, fungicides, chemical reagents, growth regulating substances, parasiticides, sex sterilants, fertility promoters, biocides, rodenticides, disinfectants, anti-oxidants, plant growth promoters, preservatives, 25 fermentation agents, fertility inhibitors, deodorants, micro-organism attenuators, catalysts, food supplements, cosmetics, vitamins, and other agents that benefit the environment of use.

The osmotic device of the invention may be used in biological environments, aquariums, industrial warehouses, laboratory facilities, hospitals, chemical reactions and 30 other facilities.

- 16 -

In one embodiment, oxybutynin and the second drug are released concurrently from a dosage form when the two drugs are included together in, for example, a tablet core, powder, capsule, bead, granule, liquid, paste, gel, cream, ointment, patch, implant or other similar dosage form capable of simultaneously delivering two or more drugs.

5 In another embodiment, oxybutynin and the second drug are released sequentially from a dosage form when the first drug is included in one part of a dosage form and the second drug is included in another part of the same dosage form, and release of the second drug begins shortly after, during or nearly at the end of completion of release of the first drug. Such dosage form would include, for example, those wherein the first drug is
10 included in a core and the second drug is included in a coat surrounding the core, a bi-layered tablet with each drug being in a different part of the core, a dosage form providing a rapid release of the first drug and a controlled release of the second drug. Suitable dosage forms for this embodiment include, for example, a layered patch, layered or coated tablet or bead, layered or coated osmotic device, capsule containing a mixture of beads
15 that provide different release profiles for the drugs, layered or coated implant, or an admixture of two compositions each containing a drug.

In yet another embodiment, oxybutynin and the second drug are released in spaced apart periods of time from a dosage form such that the first drug is released during a first period of time and the second drug is released during a later second period of time.
20 Dosage forms suitable for this type of release are generally considered targeted, enteric or timed-release dosage forms. Suitable dosage forms for this embodiment include, for example, a layered patch, layered or coated tablet, layered or coated osmotic device, capsule containing a mixture of beads that provide different release profiles for the drugs, and layered or coated implant.

25 Each drug will be released independently from a solid dosage form according to a rapid, immediate, controlled, sustained, slow, timed, targeted, pseudo-first order, first order, pseudo-zero order, zero-order and/or delayed release profile. The particular release profiles for oxybutynin and the second drug in a particular dosage form will depend upon the specific combination of oxybutynin and second drug present and the
30 excipients used to make the dosage form. For example, a dosage form might provide: 1) a controlled release of the first drug and a controlled release of the second drug; 2) a controlled release of the second drug and a rapid release of the first drug; 3) a controlled

Marked up Version of Claims

- 59 -

CLAIMS

We claim:

- 1) (Amended) A pharmaceutical composition comprising:
 - a) oxybutynin;
 - b) a second drug for treating incontinence, wherein the second drug is selected from the group consisting of darifenacin, duloxetine and tolterodine; and
 - c) at least one pharmaceutical excipient.
- 2) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is present as a manufactured batch.
- 3) The pharmaceutical composition of claim 2 comprising:
 - a) a homogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 4) The pharmaceutical composition of claim 2 comprising:
 - a) a heterogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 5) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is present as a unit dose.
- 6) The pharmaceutical composition of claim 5, wherein at least one of the oxybutynin and the second drug is present in a therapeutically effective amount.
- 7) The pharmaceutical composition of claim 5, wherein the oxybutynin and the second drug are each present in a therapeutically effective amount.
- 8) The pharmaceutical composition of claim 5, wherein at least one of the oxybutynin and the second drug is present in a sub-therapeutically effective amount.
- 9) The pharmaceutical composition of claim 5, wherein the oxybutynin and the second drug are present in sub-therapeutically effective amounts.
- 10) The pharmaceutical composition of claim 5 comprising:
 - a) a homogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 11) The pharmaceutical composition of claim 5 comprising:
 - a) a heterogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.

- 60 -

- 12) The pharmaceutical composition of claim 1, 2 or 5, wherein the weight ratio of oxybutynin to second drug ranges from 1:0.1 to 1:20.
- 13) (Amended) A dosage form comprising:
 - a) oxybutynin;
 - b) a second drug for treating incontinence, wherein the second drugs is selected from the group consisting of darifenacin, duloxetine and tolterodine; and
 - c) at least one pharmaceutical excipient.
- 14) The dosage form of claim 13 comprising:
 - a) a first composition comprising oxybutynin and at least one pharmaceutical excipient; and
 - b) a different second composition comprising the second drug and at least one pharmaceutical excipient.
- 15) The dosage form of claim 14, wherein the first and second compositions are in admixture.
- 16) The dosage form of claim 14, wherein the first and second compositions are separate.
- 17) The dosage form of claim 16, wherein the first and second compositions are in contact with one another.
- 18) The dosage form of claim 13, wherein at least one of the oxybutynin and the second drug is present in a sub-therapeutically effective amount
- 19) The dosage form of claim 18, wherein the oxybutynin and second drug together provide a synergistic therapeutic effect when the dosage form is administered to a subject.
- 20) The dosage form of claim 13, wherein the oxybutynin and second drug are present in therapeutically effective amounts.
- 21) The dosage form of claim 13, wherein the release profile for oxybutynin and the second drug is independently selected from a controlled, delayed, extended, pulsatile, sustained, immediate, timed, slow, immediate or rapid release when the dosage form is exposed to an aqueous environment.
- 22) The dosage form of claim 21, wherein oxybutynin and the second drug have approximately the same release profile.
- 23) The dosage form of claim 21, wherein oxybutynin and the second drug have different release profiles.

- 61 -

- 24) The dosage form of claim 21, wherein the dosage form provides a controlled release of oxybutynin and the second drug.
- 25) The dosage form of claim 24, wherein the dosage form provides therapeutically effective plasma levels of oxybutynin and the second drug for a period of at least 12 hours after administration when administered to a subject.
- 26) The dosage form of claim 13, wherein the dosage form, when administered to a subject, provides an improved toxicity profile as compared to oxybutynin or the second drug when either agent is administered alone to the same subject.
- 27) The dosage form of claim 13, 18, 20, 21 or 26, wherein the dosage form is selected from the group consisting of a tablet, osmotic device, capsule, tape, suspension, liquid, implant, gel, pill, cream, ointment, inhaler, paste, troche, lozenge, bead, granule, granulation, spheroid, particulate solid, reconstitutable solid, powder, extruded solid, suppository, stick, and mini-pump.
- 28) A method of treating incontinence in a subject comprising the step of administering a pharmaceutical composition according to any one of claims 1, 5, 6, 8, 10, 11.
- 29) A method of treating incontinence in a subject comprising the step of administering a dosage form according to any one of claims 13-16, 18, 20-23 or 26.
- 30) (Amended) A coated solid dosage form comprising:
 - a) a core comprising oxybutynin, a second drug for treating incontinence and at least one pharmaceutical excipient, wherein the second drug is selected from the group consisting of darifenacin, duloxetine and tolterodine; and
 - b) a wall enveloping the core.
- 31) The dosage form of claim 30, wherein the core comprises:
 - a) a first composition comprising oxybutynin and at least one pharmaceutical excipient; and
 - b) a different second composition comprising the second drug and at least one pharmaceutical excipient.
- 32) The dosage form of claim 31, wherein the first and second compositions are in admixture.
- 33) The dosage form of claim 31, wherein the first and second compositions are separate.
- 34) The dosage form of claim 33, wherein the first and second compositions are in contact with one another.

- 63 -

48) The dosage form of claim 47, wherein the wall is water soluble or water erodible.

49) ~~[An osmotic device comprising:~~

- ~~a) a core comprising a first composition comprising a first drug and at least one pharmaceutical excipient, and a different second composition comprising a second drug and at least one pharmaceutical excipient, wherein the first and second compositions contact one another and are in stacked arrangement; and~~
- ~~b) a membrane enveloping the core and having at least two passageways to permit a controlled release of the first and second drugs from the core when the osmotic device is exposed to an aqueous environment, wherein at least one first passageway is in communication with the first composition and at least one second passageway is in communication with the second composition.~~

50) ~~The osmotic device of claim 49, wherein the membrane is semipermeable.~~

51) ~~The osmotic device of claim 49 further comprising at least one external coat exterior to the membrane.~~

52) ~~The osmotic device of claim 51, wherein the external coat is independently selected at each occurrence from water soluble and water erodible.~~

53) ~~The osmotic device of claim 51, wherein the external coat is independently selected at each occurrence from inert and drug containing.~~

54) ~~The osmotic device of claim 51, wherein the external coat is independently selected at each occurrence from microporous, permeable, semipermeable and impermeable.~~

55) ~~The osmotic device of claim 49 further comprising at least one internal coat interposed the core and the membrane.~~

56) ~~The osmotic device of claim 55, wherein the internal coat is independently selected at each occurrence from water soluble and water erodible.~~

57) ~~The osmotic device of claim 55, wherein the internal coat is independently selected at each occurrence from inert and drug containing.~~

58) ~~The osmotic device of claim 55, wherein the internal coat is independently selected at each occurrence from microporous, permeable, semipermeable and impermeable.~~

59) ~~The osmotic device of claim 49, wherein the first drug and the second drug are released sequentially or in an overlapping manner when the osmotic device is exposed to an aqueous environment.~~

- 64 -

- 60) ~~The osmotic device of claim 49 further comprising an external coat surrounding the semipermeable membrane, wherein the first passageway has been formed after application of the external coat to the semipermeable membrane and the second passageway has been formed before application of the external coat to the semipermeable membrane such that the second passageway is plugged by the external coat and release of the second drug begins after release of the first drug has started.~~
- 61) ~~The osmotic device of claim 49 further comprising an external coat surrounding the semipermeable membrane, wherein the first and second passageways have been formed before application of the external coat to the semipermeable membrane; the first and second passageways are plugged by the external coat; and release of the first drug and the second drug is delayed for a period of time after exposure to an aqueous environment.~~
- 62) ~~The osmotic device of claim 50, wherein the first drug and the second drug are released sequentially or in an overlapping manner when the osmotic device is exposed to an aqueous environment.~~
- 63) ~~The osmotic device of claim 49, 50, 51, 55, 59 or 62, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.]~~
- 64) (Amended) An osmotic device comprising:
- a) a core comprising a first composition comprising oxybutynin and at least one pharmaceutical excipient, and a different second composition comprising a second drug, selected from the group consisting of darifenacin, duloxetine and tolterodine, and at least one pharmaceutical excipient; and
 - b) a semipermeable membrane enveloping the core and having at least two passageways to permit controlled release of oxybutynin and the second drug from the core when the osmotic device is exposed to an aqueous environment, wherein at least one passageway is in communication with the first composition and at least one passageway is in communication with the second composition.
- 65) The osmotic device of claim 64, wherein the first and second compositions contact one another and are in stacked arrangement.

- 65 -

- 66) The osmotic device of claim 64, wherein, when the osmotic device is exposed to an aqueous environment, oxybutynin is released approximately as follows:

Time (hours)	Minimum Amount Released (%)	Maximum Amount Released (%)
1	0	10
3	5	25
7	20	50
11	40	70
15	58	84
19	70	89
24	76	100

- 67) The osmotic device of claim 66, wherein the osmotic device provides plasma levels for oxybutynin in the range of about 1-12 ng per ml of plasma.

- 68) The osmotic device of claim 64, wherein, the second drug is darifenacin and is released approximately as follows when the osmotic device is exposed to an aqueous environment:

Time (hours)	Minimum Amount Released (%)	Maximum Amount Released (%)
1	0	12
3	10	35
7	25	65
11	45	89
15	90	98
24	89	100

- 69) The osmotic device of claim 64 or 65, the second drug is darifenacin and is released approximately as follows when the osmotic device is exposed to an aqueous environment:

Time (hours)	Minimum Amount Released (%)	Maximum Amount Released (%)
1	0	5
3	0	15
7	10	45
11	29	74
15	52	84

- 66 -

Time (hours)	Minimum Amount Released (%)	Maximum Amount Released (%)
19	60	89
24	80	100

70) The osmotic device of claim 64 or 65, wherein the second drug is tolterodine and is released approximately as follows when the osmotic device is exposed to an aqueous environment:

Time (hours)	Minimum Amount Released (%)	Maximum Amount Released (%)
1	0	12
3	3	25
5	17	36
7	31	50
9	49	66
11	61	76
15	74	90
24	76	100

71) The osmotic device of claim 64 or 65, wherein the release of oxybutynin and/or the second drug is delayed.

72) A method of treating incontinence in a subject comprising the step of administering a dosage form according to claim 36.

73) A method of treating incontinence in a subject comprising the step of administering a dosage form according to claim 30-33, 41, 42, 44 or 47.

74) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 64-66 or 68.

75) ~~A dual-controlled release osmotic device comprising:~~

~~a) a core comprising a first active agent-containing layer and a second active agent-containing layer; and~~

~~b) a semipermeable membrane surrounding the core, wherein the membrane comprises at least one preformed passageway in communication with at least one of the first and second active agent-containing layers;~~

~~whereby the osmotic device provides a controlled release of the first active agent through the at least one preformed passageway according to a first release profile and the~~

- 67 -

~~second layer provides a controlled release of the second active through the at least one preformed passageway according to a second release profile.~~

~~76) The osmotic device of claim 75, wherein the layers are in stacked arrangement and in contact with one another.~~

~~77) The osmotic device of claim 75, wherein the second active agent-containing layer surrounds the first active agent-containing layer.~~

~~78) The osmotic device of claim 76 or 77, wherein the osmotic device comprises at least one first preformed passageway in communication with the first active agent-containing layer and at least one second preformed passageway in communication with the second active agent-containing layer.~~

~~79) The osmotic device of claim 76 or 77, wherein the membrane comprises at least one preformed passageway in communication with both the first and second active agent-containing layers.~~

~~80) The osmotic device of claim 76 or 77, wherein the membrane comprises at least two preformed passageways and at least one of the two preformed passageways is plugged with a water soluble or water erodible material.~~

~~81) The osmotic device of claim 76 or 77, wherein the membrane comprises at least two preformed passageways both of which are plugged with a water soluble or water erodible material, wherein the material plugging the first passageway is the same as the material plugging the second passageway.~~

~~82) The osmotic device of claim 76 or 77, wherein the membrane comprises at least two preformed passageways both of which are plugged with a water soluble or water erodible material, wherein the material plugging the first passageway is different than the material plugging the second passageway.~~

~~83) The osmotic device of claim 76 or 77 further comprising at least one external coat exterior to the membrane.~~

~~84) The osmotic device of claim 83, wherein the external coat is independently selected at each occurrence from water soluble and water erodible.~~

~~85) The osmotic device of claim 83, wherein the external coat is independently selected at each occurrence from inert and drug-containing.~~

~~86) The osmotic device of claim 83, wherein the external coat is independently selected at each occurrence from microporous, permeable, semipermeable and impermeable.~~

- 68 -

- ~~87) The osmotic device of claim 76 or 77 further comprising at least one internal coat interposed the core and the membrane.~~
- ~~88) The osmotic device of claim 87, wherein the internal coat is independently selected at each occurrence from water soluble and water erodible.~~
- ~~89) The osmotic device of claim 87, wherein the internal coat is independently selected at each occurrence from inert and drug-containing.~~
- ~~90) The osmotic device of claim 87, wherein the internal coat is independently selected at each occurrence from microporous, permeable, semipermeable and impermeable.~~
- ~~91) The osmotic device of claim 76 or 77, wherein the first drug and the second drug are released sequentially or in an overlapping manner when the osmotic device is exposed to an aqueous environment.~~
- ~~92) The osmotic device of claim 75 further comprising an external coat surrounding the membrane, and the membrane comprises at least a first preformed passageway and at least a second preformed passageway, wherein the first passageway has been formed after application of the external coat to the membrane, and the second passageway has been formed before application of the external coat to the membrane such that the second passageway is plugged by the external coat, and release of the second drug begins after release of the first drug has started.~~
- ~~93) The osmotic device of claim 75 further comprising an external coat surrounding the membrane, and the membrane comprises at least a first preformed passageway and at least a second preformed passageway, wherein the first and second passageways have been formed before application of the external coat to the membrane; and the first and second passageways are plugged by the external coat.~~
- ~~94) The osmotic device of claim 93, wherein release of the first drug and the second drug is delayed for a period of time after exposure to an aqueous environment.~~
- ~~95) The osmotic device of claims any one of claims 75, 76 or 77, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- ~~96) The osmotic device of claim 78, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~

- 69 -

- 97) ~~The osmotic device of claim 79, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 98) ~~The osmotic device of claim 80, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 99) ~~The osmotic device of claim 81, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 100) ~~The osmotic device of claim 82, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 101) ~~The osmotic device of claim 83, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 102) ~~The osmotic device of claim 87, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 103) ~~The osmotic device of claim 91, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 104) ~~The osmotic device of claim 92 or 93, wherein each drug is independently released according to a timed, targeted, pseudo first order, first order, pseudo zero order, zero order, second order and/or delayed release profile.~~
- 105) ~~The dosage form of claim 16, wherein the first and second compositions are not in contact with one another.]~~
- 106) The dosage form of claim 14, wherein at least one of the oxybutynin and the second drug is present in a sub-therapeutically effective amount
- 107) The dosage form of claim 14, wherein the oxybutynin and second drug are present in therapeutically effective amounts.
- 108) The dosage form of claim 13 comprising:

- 70 -

- a) a homogeneous or homogeneous mixture of oxybutynin, the second drug and at least one pharmaceutical excipient.
- 109) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 69.
- 110) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 70.
- 111) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 71.
- 112) (Amended) An osmotic device comprising:
- a) a core comprising a first composition comprising oxybutynin and at least one pharmaceutical excipient, and a different second composition comprising a second drug, selected from the group consisting of darifenacin, duloxetine and tolterodine, and at least one pharmaceutical excipient, wherein the first and second compositions contact one another and are in stacked arrangement; and
- b) a semipermeable membrane enveloping the core and having at least two passageways to permit controlled release of oxybutynin and the second drug from the core when the osmotic device is exposed to an aqueous environment, wherein at least one passageway is in communication with the first composition and at least one passageway is in communication with the second composition;
- wherein, when the osmotic device is exposed to an aqueous environment, oxybutynin is released approximately as follows:

Time (hs)	Amount Released (%)	
	Min	Max
1	0	10
3	5	25
5	17	36
7	20	50
11	40	70
15	58	85
19	70	90
24	76	100

- 113) The osmotic device of claim 112, wherein, when the osmotic device is exposed to an aqueous environment, the second drug is released approximately as follows:

- 71 -

Time (hs)	Amount Range (%)	
	Min	Max
1	0	12
3	3	25
5	17	36
7	31	50
9	49	66
11	61	76
15	74	90
24	76	100

- 114) The osmotic device of claim 112 or 113, wherein the second drug is darifenacin, and the osmotic device provides a single dose plasma level for darifenacin that is sufficient to provide the desired therapeutic response.
- 115) The osmotic device of claim 112 or 113, wherein the second drug is tolterodine, and the osmotic device provides a single dose plasma level for tolterodine in the range of about 0.5 to 25 ng per ml of plasma.
- 116) The osmotic device of claim 112 further comprising at least one external coat exterior to the membrane.
- 117) The osmotic device of claim 116, wherein the external coat is independently selected at each occurrence from water soluble and water erodible.
- 118) The osmotic device of claim 116, wherein the external coat is independently selected at each occurrence from inert and drug-containing.
- 119) The osmotic device of claim 116, wherein the external coat is independently selected at each occurrence from microporous, permeable, semipermeable and impermeable.
- 120) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 112, 113, 116-118 or 119.
- 121) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 114.
- 122) A method of treating incontinence in a subject comprising the step of administering an osmotic device according to claim 115.
- 123) ~~[A method of treating incontinence comprising the step of administering to a subject in need thereof oxybutynin and darifenacin.]~~

- 72 -

- 124) ~~The method of claim 123 wherein the oxybutynin and darifenacin are in the same dosage form.~~
- 125) ~~The method of claim 124 wherein the oxybutynin and darifenacin are released from the dosage form in a controlled manner over an extended period of time.~~
- 126) ~~The method of claim 123 wherein the oxybutynin and darifenacin are in separate dosage forms.~~
- 127) ~~The method of claim 126 wherein the oxybutynin and darifenacin are released from their respective dosage forms in a controlled manner over an extended period of time.~~
- 128) ~~A method of treating incontinence comprising the step of administering to a subject in need thereof oxybutynin and tolterodine.~~
- 129) ~~The method of claim 128 wherein the oxybutynin and tolterodine are in the same dosage form.~~
- 130) ~~The method of claim 129 wherein the oxybutynin and tolterodine are released from the dosage form in a controlled manner over an extended period of time.~~
- 131) ~~The method of claim 128 wherein the oxybutynin and tolterodine are in separate dosage forms.~~
- 132) ~~The method of claim 131 wherein the oxybutynin and tolterodine are released from their respective dosage forms in a controlled manner over an extended period of time.]~~